ADARx Pharmaceuticals, Inc. (ADRX)
12.67
-1.49
(-10.52%)
USD |
NASDAQ |
Nov 20, 16:00
12.67
0.00 (0.00%)
After-Hours: 16:15
ADARx Pharmaceuticals Enterprise Value : 624.20M for Nov. 19, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 19, 2026 | 624.20M |
| November 18, 2026 | 480.47M |
| November 17, 2026 | 587.73M |
| November 16, 2026 | 607.04M |
| November 13, 2026 | 628.49M |
| November 12, 2026 | 704.64M |
| November 11, 2026 | 531.96M |
| November 10, 2026 | 560.92M |
| November 09, 2026 | 585.58M |
| November 06, 2026 | 524.45M |
| November 05, 2026 | 530.88M |
| November 04, 2026 | 710.00M |
| November 03, 2026 | 831.20M |
| November 02, 2026 | 795.81M |
| October 30, 2026 | 928.80M |
| October 29, 2026 | 1.020B |
| October 28, 2026 | 1.031B |
| October 27, 2026 | 1.050B |
| October 26, 2026 | 1.016B |
| October 23, 2026 | 996.38M |
| October 22, 2026 | 1.002B |
| Date | Value |
|---|---|
| October 21, 2026 | 942.75M |
| October 20, 2026 | 1.002B |
| October 19, 2026 | 996.38M |
| October 16, 2026 | 998.52M |
| October 15, 2026 | 1.004B |
| October 14, 2026 | 1.018B |
| October 13, 2026 | 1.004B |
| October 12, 2026 | 1.033B |
| October 09, 2026 | 1.012B |
| October 08, 2026 | 1.001B |
| October 07, 2026 | 964.20M |
| October 06, 2026 | 1.098B |
| October 05, 2026 | 1.149B |
| October 02, 2026 | 1.063B |
| October 01, 2026 | 1.201B |
| September 30, 2026 | 1.244B |
| September 29, 2026 | 2.141B |
| September 28, 2026 | 2.083B |
| September 25, 2026 | 2.004B |
| September 24, 2026 | 1.753B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Korsana Biosciences, Inc. | 1.184B |
| IRulya Therapeutics, Inc. | 79.19M |
| PepGen Inc. | 183.00M |
| Q32 Bio, Inc. | -30.98M |
| Bridgebio Oncology Therapeutics, Inc. | -42.25M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -28.12M |
| Revenue (Quarterly) | 2.217M |
| Total Expenses (Quarterly) | 30.33M |
| EPS Diluted (Quarterly) | -0.2749 |
| Gross Profit Margin (Quarterly) | 66.26% |
| Profit Margin (Quarterly) | -1.27K% |
| Earnings Yield | -7.09% |
| Normalized Earnings Yield | -6.985 |